Literature DB >> 30254790

Metabolic Changes in Patients with Schizophrenia Switched From Olanzapine to Asenapine or Clozapine.

Masaru Nakamura1,2, Takahiko Nagamine1,2.   

Abstract

Entities:  

Year:  2018        PMID： 30254790      PMCID： PMC6145608     

Source DB:  PubMed          Journal:  Innov Clin Neurosci        ISSN： 2158-8333


× No keyword cloud information.
  9 in total

Review 1.  A short history of the 5-HT2C receptor: from the choroid plexus to depression, obesity and addiction treatment.

Authors:  Jose M Palacios; Angel Pazos; Daniel Hoyer
Journal:  Psychopharmacology (Berl)       Date:  2017-03-07       Impact factor: 4.530

2.  Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes.

Authors:  J S Silvestre; J Prous
Journal:  Methods Find Exp Clin Pharmacol       Date:  2005-06

3.  H1-histamine receptor affinity predicts weight gain with antidepressants.

Authors:  Virginio Salvi; Claudio Mencacci; Francesco Barone-Adesi
Journal:  Eur Neuropsychopharmacol       Date:  2016-09-01       Impact factor: 4.600

Review 4.  Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.

Authors:  Marc De Hert; Weiping Yu; Johan Detraux; Kim Sweers; Ruud van Winkel; Christoph U Correll
Journal:  CNS Drugs       Date:  2012-09-01       Impact factor: 5.749

5.  Role of serotonin 5-HT2C and histamine H1 receptors in antipsychotic-induced diabetes: A pharmacoepidemiological-pharmacodynamic study in VigiBase.

Authors:  François Montastruc; Aurore Palmaro; Haleh Bagheri; Laurent Schmitt; Jean-Louis Montastruc; Maryse Lapeyre-Mestre
Journal:  Eur Neuropsychopharmacol       Date:  2015-07-21       Impact factor: 4.600

6.  Hyperactivity and reduced energy cost of physical activity in serotonin 5-HT(2C) receptor mutant mice.

Authors:  Katsunori Nonogaki; Luna Abdallah; Evan H Goulding; Stephen J Bonasera; Laurence H Tecott
Journal:  Diabetes       Date:  2003-02       Impact factor: 9.461

7.  Asenapine: a novel psychopharmacologic agent with a unique human receptor signature.

Authors:  M Shahid; G B Walker; S H Zorn; E H F Wong
Journal:  J Psychopharmacol       Date:  2008-02-28       Impact factor: 4.153

8.  Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1.

Authors:  Jonathan M Meyer; Vicki G Davis; Donald C Goff; Joseph P McEvoy; Henry A Nasrallah; Sonia M Davis; Robert A Rosenheck; Gail L Daumit; John Hsiao; Marvin S Swartz; T Scott Stroup; Jeffrey A Lieberman
Journal:  Schizophr Res       Date:  2008-02-06       Impact factor: 4.939

9.  Impact of Muscarinic M3 Receptor Antagonism on the Risk of Type 2 Diabetes in Antidepressant-Treated Patients: A Case-Controlled Study.

Authors:  Yen-Hao Tran; Catharina C M Schuiling-Veninga; Jorieke E H Bergman; Henk Groen; Bob Wilffert
Journal:  CNS Drugs       Date:  2017-06       Impact factor: 5.749
  9 in total
  2 in total

1.  Impact of Lurasidone on Metabolic Parameters and Prolactin Levels Based on Differences of Psychiatric Diagnosis, Dosage, and Introducing Methods: An Observational Study.

Authors:  Masaru Nakamura; Takahiko Nagamine
Journal:  Innov Clin Neurosci       Date:  2022 Apr-Jun

2.  Brexpiprazole as a New Serotonin-Dopamine Receptor Modulator: Considering the Clinical Relevance for Metabolic Parameters and Prolactin Levels.

Authors:  Masaru Nakamura; Takahiko Nagamine
Journal:  Innov Clin Neurosci       Date:  2019-09-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.